目的探究抗新生血管药物与玻璃体切割视网膜复位术联合治疗严重增殖性糖尿病视网膜病变的应用效果。方法整群选取该院2014年10月—2015年8月收治的40例48眼的严重PDR患者的临床资料进行回顾性分析,全部患者均进行雷珠单抗（lucentis）...目的探究抗新生血管药物与玻璃体切割视网膜复位术联合治疗严重增殖性糖尿病视网膜病变的应用效果。方法整群选取该院2014年10月—2015年8月收治的40例48眼的严重PDR患者的临床资料进行回顾性分析,全部患者均进行雷珠单抗（lucentis）联合玻璃体切除手术眼内填充硅油（或者是惰性气体）。结果全部手术患者在术中的出血情况较少;48例眼中,采用玻璃体腔填充20%的C3F8 14例,填充16%C3F8 25例,玻璃体腔填充硅油的有9例,在手术后的14~28 d后进行眼底彩色荧光造影,且逐渐将PRP有效完成。术后的眼压为13~35 mm Hg,选择降低眼压药物对局部进行点眼后,都能够将眼压控制在〈20 mm Hg内,最佳的矫正视力为0.07~0.4。结论抗新生血管药物与玻璃体切割视网膜复位术联合治疗严重增殖性糖尿病视网膜病变的效果显著,可以将术中出血情况明显减少,降低术后并发症发生率,促使患者术后最佳矫正视力明显提高。展开更多
Aim: To compare the anatomical and functional success of primary scleral buckling, performed either alone or in combination with vitrectomy, for primary retinal detachment (RD) in phakic eyes and in eyes had undergone...Aim: To compare the anatomical and functional success of primary scleral buckling, performed either alone or in combination with vitrectomy, for primary retinal detachment (RD) in phakic eyes and in eyes had undergone uneventful phacoemulsification and had received posterior chamber lens implantations. Methods: A total of 243 consecutive patients were included in this retrospective, nonrandomized comparative study. In all, 165 phakic and 78 pseudophakic individuals with primary RD underwent scleral buckling alone or in combination with vitrectomy and were followed up for 6 months. Pre-intra-and postoperative findings including anatomical success, best-corrected visual acuity (BCVA), complications, and the development of proliferative vitreoretinopathy (PVR), macular pucker, or secondary cataracts were recorded. Cases requiring more than one surgical intervention were defined having failed, although further surgical intervention might have led to success. Results: At 6 months after scleral buckling alone, the anatomical success was similar in phakic (88.98% ) and pseudophakic (87.65% ) eyes (log rank=0.310). The corresponding results after scleral buckling with vitrectomy were 82.13 and 77.63% for phakic and pseudophakic eyes, respectively (log rank= 0.799). At 6 months after scleral buckling alone, BCVA was similar in phakic and pseudophakic eyes (0.62 ± 0.30 vs 0.70 ± 0.29; P=0.227). Likewise, after scleral buckling with vitrectomy, BCVA did not differ significantly (P=0.322) between phakic (0.34 ± 0.32) and pseudophakic eyes (0.50 ± 0.27). Conclusion: The anatomical and functional outcome of primary retinal reattachment surgery, involving scleral buckling alone or in combination with vitrectomy, is similar in phakic and pseudophakic eyes.展开更多
文摘目的探究抗新生血管药物与玻璃体切割视网膜复位术联合治疗严重增殖性糖尿病视网膜病变的应用效果。方法整群选取该院2014年10月—2015年8月收治的40例48眼的严重PDR患者的临床资料进行回顾性分析,全部患者均进行雷珠单抗（lucentis）联合玻璃体切除手术眼内填充硅油（或者是惰性气体）。结果全部手术患者在术中的出血情况较少;48例眼中,采用玻璃体腔填充20%的C3F8 14例,填充16%C3F8 25例,玻璃体腔填充硅油的有9例,在手术后的14~28 d后进行眼底彩色荧光造影,且逐渐将PRP有效完成。术后的眼压为13~35 mm Hg,选择降低眼压药物对局部进行点眼后,都能够将眼压控制在〈20 mm Hg内,最佳的矫正视力为0.07~0.4。结论抗新生血管药物与玻璃体切割视网膜复位术联合治疗严重增殖性糖尿病视网膜病变的效果显著,可以将术中出血情况明显减少,降低术后并发症发生率,促使患者术后最佳矫正视力明显提高。
文摘Aim: To compare the anatomical and functional success of primary scleral buckling, performed either alone or in combination with vitrectomy, for primary retinal detachment (RD) in phakic eyes and in eyes had undergone uneventful phacoemulsification and had received posterior chamber lens implantations. Methods: A total of 243 consecutive patients were included in this retrospective, nonrandomized comparative study. In all, 165 phakic and 78 pseudophakic individuals with primary RD underwent scleral buckling alone or in combination with vitrectomy and were followed up for 6 months. Pre-intra-and postoperative findings including anatomical success, best-corrected visual acuity (BCVA), complications, and the development of proliferative vitreoretinopathy (PVR), macular pucker, or secondary cataracts were recorded. Cases requiring more than one surgical intervention were defined having failed, although further surgical intervention might have led to success. Results: At 6 months after scleral buckling alone, the anatomical success was similar in phakic (88.98% ) and pseudophakic (87.65% ) eyes (log rank=0.310). The corresponding results after scleral buckling with vitrectomy were 82.13 and 77.63% for phakic and pseudophakic eyes, respectively (log rank= 0.799). At 6 months after scleral buckling alone, BCVA was similar in phakic and pseudophakic eyes (0.62 ± 0.30 vs 0.70 ± 0.29; P=0.227). Likewise, after scleral buckling with vitrectomy, BCVA did not differ significantly (P=0.322) between phakic (0.34 ± 0.32) and pseudophakic eyes (0.50 ± 0.27). Conclusion: The anatomical and functional outcome of primary retinal reattachment surgery, involving scleral buckling alone or in combination with vitrectomy, is similar in phakic and pseudophakic eyes.
